(Q34434828)

2 August 2017

1 reference

title

Monitoring drug resistance in leishmaniasis (English)

1 reference

2 August 2017

Croft SL

1

1 reference

2 August 2017

publication date

1 November 2001

1 reference

Tropical Medicine and International Health

2 August 2017

published in

1 reference

2 August 2017

volume

6

1 reference

2 August 2017

issue

11

1 reference

2 August 2017

page(s)

899-905

1 reference

Pharmacokinetics of antimony in patients treated with sodium stibogluconate for cutaneous leishmaniasis.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

Involvement of thiol metabolism in resistance to glucantime in Leishmania tropica

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

Comparative effects of 4-aminopyrazolopyrimidine, its 2'-deoxyriboside derivative, and allopurinol on in vitro growth of American Leishmania species

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

Isolation of genes mediating resistance to inhibitors of nucleoside and ergosterol metabolism in Leishmania by overexpression/selection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

A Revised Classification for Leishmania and Endotrypanum

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: A double-blind control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

Topical treatment of New and Old World cutaneous leishmaniasis in experimental animals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

Decreased sensitivity to meglumine antimoniate (Glucantime) ofLeishmania infantumisolated from dogs after several courses of drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

Leishmania spp.: development of pentostam-resistant clones in vitro by discontinuous drug exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

Leishmania resistant to sodium stibogluconate: drug-associated macrophage-dependent killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

Evidence that the High Incidence of Treatment Failures in Indian Kala‐Azar Is Due to the Emergence of Antimony‐Resistant Strains ofLeishmania donovani

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

Placebo-Controlled Clinical Trial of Sodium Stibogluconate (Pentostam) versus Ketoconazole for Treating Cutaneous Leishmaniasis in Guatemala

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

The sensitivity of Leishmania species to aminosidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

In vitro antileishmanial properties of tri- and pentavalent antimonial preparations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

Phase 2 efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

Molecular mechanisms of drug resistance in fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3156.2001.00754.X

10.1046/J.1365-3156.2001.00754.X

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference